One of the most consequential changes in 2026 is the loss of exclusivity for semaglutide, beginning in early 2026 across major markets including India, China, Brazil, Turkey and Canada, with semaglutide having lost exclusivity in India on 20th March 2026
You might be on the fence right now or want something a little less aggressive toward weight loss
Key benefits including neurologic benefits, neuroplasticity, as well as a reduction in neuroinflammation, myth busting and false narratives specific to the use of these drugs, including concerns over dosing relevant to gastroparesis, too fast to titration, monotherapy, lack of strength training, gallbladder issues and so much more
Helicobacter pylori infection induces oxidative stress and programmed cell death in human gastric epithelial cells
10.1007/s10741-021-10157-y 18 CosentinoF.GrantP